Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effects of XueZhiTong capsules on chronic kidney disease patients with dyslipidemia
Abstract
Purpose: To determine the clinical effectiveness of Xuezhitong capsule in chronic kidney disease (CKD) patients with dyslipidemia, and its influence on inflammation and oxidative stress.
Methods: Ninety CKD patients with dyslipidemia who were admitted to the Department of Nephrology of our hospital from January 2018 to January 2020 were randomly assigned to group A (treated with Xuezhitong capsules), group B (treated with combination of Xuezhitong capsules and atorvastatin), and group C (treated with atorvastatin), with 30 cases in each group. Renal function, lipid indicators, inflammatory indicators, and degree of oxidative stress were compared among the three groups of patients after 3 consecutive months of treatment.
Results: At 3 months after treatment, estimated glomerular filtration rate (eGFR) and urinary albumin creatinine ratio (UACR) were markedly decreased in all three groups (p < 0.05). After treatment, the levels of TC, TGs, and LDL-C were decreased markedly and time-dependently in the three groups, with the lowest levels in group B, while HDL-C level was elevated with treatment time, with the highest level in group B (p < 0.05). After treatment, the 3 groups exhibited significant decreases in levels of hypersensitive C-reactive protein (hs-CRP), homocysteine (Hcy), and malondialdehyde (MDA), with the lowest levels in group B (p < 0.05). Adiponectin level was significantly increased in each of the 3 groups (p < 0.05).
Conclusion: Xuezhitong capsules exerted lipid-lowering effect and mitigated inflammation and oxidative stress in CKD patients with dyslipidemia, without any adverse effects. This finding provides a new treatment option for elderly CKD patients with dyslipidemia.
